Akif TURNA, Ezel ERSEN, İsmail SARBAY, Mehlika İŞCAN, Merve EKİNCİ, H. Volkan KARA

Pulmoner Aspergillomada Uzun Dönem Antifungal Tedavi Cerrahiye Alternatif Olabilir mi?

Pulmoner aspergilloma (PA), immünsüprese hastalarda yüksek mortalite ve morbiditeli klinik durumlardandır. Tedavide sıklıkla cerrahi rezeksiyon tercih edilir; fakat cerrahide lokal ve sistemik yayılım riski mevcuttur ve ayrıca cerrahi tedaviye fonksiyonel olarak uygun olmayan hastalar da vardır. Bu çalışmada cerrahi ve antifungal tedavi uygulanmış olan bilateral PA’lı iki hastayı sunmaktayız. Vorikonazol ile yapılan ve iki hastamızda da başarılı olan antifungal tedavi, cerrahiye uygun olmayan bir grup PA hastası için ümit verici bir yaklaşım olabilir.

Can Long-term Antifungal Therapy Be an Alternative to Surgery in Pulmonary Aspergilloma?

Pulmonary aspergilloma is one of the clinical conditions with high mortality and morbidityin immunosuppressed patients. Surgical resection has been the leading treatment option;however, surgical treatment involves some risk of local and systemic dissemination andthere are also patients who are functionally inappropriate to be treated surgically. In thispaper, we present two patients with bilateral PA who underwent surgical and antifungaltreatment. Antifungal therapy with voriconazole that was successful for both of our patientsmight be a promising approach to a group of PA patients who are not appropriatefor surgery.

PDF

___

Regnard JF, Icard P, Nicolasi M, et al. Aspergilloma: a series of 89 surgical cases. Ann Thorac Surg. 2000;69:898– 903.
Babatasi G, Massetti M, Chapelier A, et al. Surgical treatment of pulmonary aspergilloma: current outcome. J Thorac Cardiovasc Surg. 2000;906–12.
Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15.
el Oakley R, Petrou M, Goldstraw P. Indications and outcome of surgery for pulmonary aspergilloma. Thorax. 1997;52:813–5.
Jewkes J, Kay PH, Paneth M, Citron KM. Pulmonary aspergilloma: analysis of prognosis in relation to haemoptysis and survey of treatment. Thorax. 1983;38:572–8.
Odev K. Toraks Radyolojisi, 2. ed. Nobel Tıp Kitabevleri; 2010:214–5.
British Thoracic and Tuberculosis Association. Aspergilloma and residual tuberculous cavities: the results of re-survey. Tubercle. 1970;51:227–45.
Scott SM, Takara T, Varkey B, et al. Thoracic mycotic and actinomycotic infections. In: W. Shields (ed.), General Thoracic Surgery. Baltimore: Williams and Wilkins; 1994:986.
Calandra T, Marchetti O. Clinical trials of antifungal prophylaxis among patients undergoing surgery. Clin Infect Dis. 2004;39(suppl 4):S185–92.
Ho KM, Lipman J, Dobb GJ, Webb SA. The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis. Crit Care. 2005;9:R710–7.
Jewkes J, Kay PH, Paneth M, Citron KM. Pulmonary aspergilloma: analysis of prognosis in relation to haemopt ysis and survey of treatment. Thorax. 1983;38:572–8.
Seki M, Maesaki S, Hashiguchi K, et al. Aspergillus fumigatus isolated from blood samples of a patient with pulmonary aspergilloma after embolization. Intern Med. 2000;39:188–90.
Campbell JH, Winter JH, Richardson MD, Shankland GS, Banham SW. Treatment of pulmonary aspergilloma with itraconazole. Thorax. 1991;46:839–41.
Park CK, Jheon S. Results of surgical treatment for pulmonary aspergilloma. Eur J Cardiothorac Surg. 2002;21:918–23.
Brik A, Salem AM, Kamal AR, et al. Surgical outcome of pulmonary aspergilloma. Eur J Cardiothorac Surg. 2008;34:882–5.
Lee JG, Lee CY, Park IK, et al. Pulmonary aspergilloma: analysis of prognosis in relation to symptoms and treatment. J Thorac Cardiovasc Surg. 2009;138:820–5.
Sagan D, Goździuk K. Surgery for pulmonary aspergilloma in immunocompetent patients: no benefit from adjuvant antifungal pharmacotherapy. Ann Thorac Surg. 2010;89(5):1603–10.